Johnson & Johnson is ending the phase 3 VENTURA clinical development program evaluating aticaprant, a selective kappa receptor antagonist, as an adjunctive treatment for major depressive disorder (MDD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback